Shots:

• The P-II (ACCORD2) study evaluates bemcentinib + SoC vs SoC alone in hospitalized patients with COVID-19
• The results showed that 90% experienced clinical response by day 29 (median 7.0 days) vs 69% (22 of 32 patients) to SoC alone (median 9.5 days), 98% received dexamethasone or an equivalent steroid in their SoC & 18% received immunomodulatory treatment with tocilizumab, antiviral remdesivir was used in 53% randomized to SoC alone & in 21% with bemcentinib
• The 2EPs showed improvements including avoidance of deterioration by ≥1-point increase in WHO score & ventilator-free survival over 29 days, 97% vs 81% were alive @day 29, was well tolerated with no relevant safety signals

Ref: PRNewswire | Image: BerGen